Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.

Al-Rashed F, AlSaeed H, Fennelly KP, Al Mulla F, Ahmad R

Open source

DOI
10.3389/fendo.2026.1900161
Published
2026
Container
Frontiers in endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2026.1900161,
  title = {Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.},
  author = {Al-Rashed F and AlSaeed H and Fennelly KP and Al Mulla F and Ahmad R},
  year = {2026},
  journal = {Frontiers in endocrinology},
  doi = {10.3389/fendo.2026.1900161},
  url = {https://doi.org/10.3389/fendo.2026.1900161}
}

RIS

TY  - JOUR
TI  - Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.
AU  - Al-Rashed F
AU  - AlSaeed H
AU  - Fennelly KP
AU  - Al Mulla F
AU  - Ahmad R
PY  - 2026
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1900161
UR  - https://doi.org/10.3389/fendo.2026.1900161
ER  - 

APA

F, A., H, A., KP, F., F, A. M., & R, A. (2026). Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1900161

Source records